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controlled trials of BTX-A for chronicmigraines. Differences were
settled via consensus. Data extraction/veriﬁcation were managed
similarly. The primary outcome was baseline-endpoint change in
migraine frequency (number/month). Heterogeneity was assessed
using c2 and I-squared. Two raters assessed study quality using the
Downs-Black scale, with adjudication via consensus. A ﬁxed-
effects model combined study results using the standardized mean
difference (Cohen’s d) in monthly migraine frequency between
placebo and BTX-A groups. RESULTS: Nine trials (N = 2114;
BTX-A = 1388, placebo = 726; 2059 completed their trials) pro-
vided data in 19 study arms and 9 placebo arms. The average age
was 43 +/- 3, duration of illness was 20 +/- 3 years, average
number of migraines was 6.0 +/- 2.1/month, 84% were females.
All c2 were non-signiﬁcant; all I-suared were 0, suggesting com-
binability and conﬁrmed using a ﬁxed-effects model. Quality
scores averaged 67% +/- 4% (“fair”; range:62%–75%). The
weighted average treatment effect (Cohen’s d) of BTX-A over
placebo was -0.05 (CI95% = -0.13, 0.03) when measured 30
days after injection, -0.04 (CI95% = -0.12, 0.04) at 60 days, and
-0.04 (CI95% = -0.12, 0.04) at 90 days post-injection. Two
comparisons out of 57 were signiﬁcant; one by Relja after 60 days
and one by Vo after 90 days. Controlling for placebo effect and
stratifying by dose stratiﬁcation found no signiﬁcant effect of
BTX-A in reducting migraine frequency per month over saline
vehicle. CONCLUSION: BTX-A used as prophylactic treatment
of chronic migraine headaches does not decrease monthly
numbers of migraines.
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OBJECTIVE: To simultaneously assess risk of acute myocardial
infarction (AMI), any cardiovascular (CV) and gastrointestinal
(GI) events with traditional non-selective NSAIDs (tNSAIDs)
and COX-2-inhibitors (coxibs). METHODS: Using the
PHARMO Record Linkage System, including drug-dispensing
and hospitalization data of >2 million residents of The Neth-
erlands, subjects with a ﬁrst hospitalization for AMI, any CV,
and GI diagnoses were identiﬁed. NSAID and coxib use was
classiﬁed into remote, recent and current use. Naproxen users
were excluded. Cases were matched to controls in a 1 to 4 ratio
on age and date. Multivariate analyses adjusted for gender,
history of hospitalizations and medications. RESULTS: Com-
pared with remote use, AMI risk was increased among current
users of coxibs combined (adjusted OR 1.63, 95% conﬁdence
interval 1.24–2.16) and among current users of tNSAIDs com-
bined (adjusted OR 1.29, 95% CI 1.08–1.55). AMI risk with
current use of celecoxib (1.63, 1.09 3.54), rofecoxib (1.59,
1.15–2.19), ibuprofen (1.54, 1.13–2.09) and diclofenac (1.43,
1.13–1.82) was signiﬁcantly increased. Risk of any CV event
with current use of celecoxib, rofecoxib, diclofenac and
tNSAIDs other than ibuprofen or diclofenac was signiﬁcantly
increased (adjusted OR ranged from 1.22 to 1.70) . GI risk
with current use of rofecoxib (1.73, 1.27–2.35), ibuprofen
(1.40, 1.00–1.95), diclofenac (4.40, 3.55–5.44) and other
tNSAIDs (2.38, 1.86–3.04), but not celecoxib (1.06, 0.47–2.35)
was signiﬁcantly increased. Compared with current use of
celecoxib, adjusted AMI and CV risk was not signiﬁcantly
increased with current use of individual coxibs and individual
tNSAIDs ,but GI risk was increased with diclofenac (adjusted
OR 4.17, 95% C.I. 1.83–9.51). CONCLUSION: AMI and CV
risk was similarly increased with individual coxibs and
tNSAIDs. Use of diclofenac strongly increased GI risk. Residual
confounding and “channelling” can not be excluded.
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CROSS-CULTURAL COMPARISONS OFTHE OVERWEIGHT/
OBESE POPULATION INTHE US AND EUROPE
Annunziata K1, Gupta S1, Chapnick J1, Pokras S2, Klingman D2
1Consumer Health Sciences, Princeton, NJ, USA, 2IMS Consulting, Falls
Church,VA, USA
OBJECTIVE: To provide cross-cultural comparisons of health
and behavior in obese individuals. METHODS: We analyzed
data from the 2006 National Health and Wellness Survey, a
cross-sectional Internet-based survey conducted annually in the
United States and EU (FR, DE, UK, SP and IT). When
weighted, the sample is representative of the country’s adult
population in terms of key sociodemographic characteristics.
The survey gathers information regarding demographics, health
conditions, quality of life, and health care use. Adults were
classiﬁed as overweight/obese (OWOB) based on BMI >= 25.
Comparisons between groups were conducted using the Chi-
square test with a signiﬁcance level of p < 0.05. RESULTS:
Almost 70% (144 M) of the United States population is
OWOB, compared to just over half of Europeans (131 M). In
both regions the OWOB populations were typically married
and employed, with a mean age of 48 yrs (USA) and 51 yrs
(EU) (p < 0.05). Both had high rates of cardiovascular
co-morbidities and a family history of obesity or diabetes. The
majority reported having less than very good health and “some/
little/no” energy in the past four weeks. Most had seen a health
care provider in the past six months (82% USA vs. 87% EU;
p < 0.05). Although many claimed to be taking steps to lose
weight (62% US vs. 50% EU; p < 0.05), most reported weight
gain over the past 6 months (30% US vs. 28% EU, p < 0.05).
Only a small portion reported taking a weight-loss prescription
(1.9% US vs. 3.5% EU, p < 0.05); but most of the remainder
would consider taking one (45% US vs. 36% EU, p < 0.05).
CONCLUSION: The obesity problem is more evident in the
United States. Americans exhibit higher rates of obesity at a
younger age but have fewer provider visits and use of prescrip-
tions, suggesting potential solutions to the problem.
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OBJECTIVE: Pain symptoms are common among adults aged
65 and older, but prevalence rates have not been updated to
reﬂect current national data. We assess prevalence among U.S.
adults aged 65 and older with respect to pain (joint, lower
back, neck, severe headaches or migraines) and describe symp-
toms by gender, obesity, and arthritis status. METHODS:
Analysis of nationally representative data collected from adults
aged 65 and older (n = 3810) participating in the National
Health and Nutrition Examination Survey (NHANES) 1999–
2004. RESULTS: Joint pain and lower back pain are the most
frequently reported type of pain, affecting 55% and 38% of
elders, respectively. Women are signiﬁcantly more likely than men
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to report joint pain, 59%vs. 49%, lower back pain, 42%vs. 33%,
and severe headaches, 12% vs. 6% (p < 0.0001 for all pain
differences). Knee joint pain is signiﬁcantly higher in women than
men (34% vs. 26%), as is ﬁnger joint pain (24% vs. 16%). Obese
older adults have a higher prevalence than non-obese elders of
knee pain (41% vs. 26%) and shoulder pain (21% vs. 16%).
Elders with arthritis are about three times more likely than elders
without arthritis to have joint pain of the knee (45% vs.14%),
ﬁnger (32% vs. 9%), shoulder (26% vs. 8%), and ankle (20% vs.
8%). CONCLUSION: Pain symptoms are highly prevalent
among older adults, particularly older women. Joint pain dispro-
portionately affects obese and arthritic older adults. These ﬁnd-
ings call for increased recognition among providers and targeted
interventions promoting symptom management and weight
reduction.
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OBJECTIVE: To examine data published over the past ten years
describing measured and self-reported obesity prevalence among
adults in Australia, Canada, France, Germany, Italy, Spain,
Sweden, the UK, and the US. METHODS: A review of the
medical literature published from 1997 to 2007 was conducted,
including MEDLINE, EMBASE, Current Contents Connect, and
International Pharmaceutical Abstracts databases; ISPOR
abstracts; and data published on the Internet by WHO and
relevant governmental agencies. RESULTS: Prevalence of obesity
varies signiﬁcantly based on the mode of measurement. Studies
based on measured weight and height report prevalence 35% to
86% higher than comparable studies based on self-reported
weight and height. Obesity prevalence has increased signiﬁcantly
during the past two to three decades for most of the countries
reviewed; prevalence in Italy, however, does not appear to have
increased dramatically. Rates of increase in prevalence for most
countries range from 40% to 60% over the past two decades.
The US has the highest prevalence of obesity worldwide
(approximately 32%). Australia, Canada, Germany, and the UK
also have relatively high obesity prevalence (range: 18% to
23%). France, Italy, Spain, and Sweden have comparatively low
obesity prevalence (range: 9% to 15%); however, rates of
increase are similar to those of countries with higher obesity
prevalence. CONCLUSION: Prevalence of obesity varies sub-
stantially among these countries. Given the rapid rate of increase
in obesity prevalence and the variation between prevalence rates
derived from measured and self-reported data, studies based on
recently collected measured data are necessary to understand
global obesity epidemiology.
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OBJECTIVE: Our primary objective was to quantify differences
in direct and indirect costs (i.e., costs of health care utilization
and costs associated with job loss, respectively), and identify
predictors of total cost based upon data provided at the
follow-up assessment. METHODS: The Carolina Lupus Study is
a population-based case-control study of SLE conducted in
eastern and central NC and SC. Controls were identiﬁed through
driver’s license records and frequency matched to cases by age,
sex, and state. The 2001 follow-up assessed health care utiliza-
tion in the past 12 months. Health care utilization per-unit
annual costs (converted to 2001 US dollars) of 198 SLE patients
were compared to those of 299 controls. The natural logarithm
was taken of health care services which were used in linear
regression to predict factors associated with an increase or
decrease in the magnitude of total annual cost for cases and
controls. RESULTS: Annual mean direct costs for health care
was $12,375 (sd $13,723) in cases compared with $3,718 (sd
$6,135) in controls (p < .0001). The annual mean salary was
$21,540 (sd 11215) among the 47 cases and $24,909 (sd 9399)
among the nine controls who had stopped working due to health
reasons. When averaged across the full follow-up sample (199
cases and 298 controls), the average annual cost of wages lost
due to illness was $5,113 and $749 in cases and controls, respec-
tively (p < 0.0001). Predictors of higher costs among cases were
lower education level (less than high school), renal disease, and
serositis. CONCLUSION: There are no published studies which
compare medical expenditure costs of SLE patients to matched-
controls. Health utilization costs were signiﬁcantly different for
nine out of the ten health services and indirect costs between
cases and controls were considerable implicating a need for
ﬁnancial support amongst minorities and women, populations
disproportionately affected by SLE.
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OBJECTIVE: The risk factors for myalgia were examined along
with other data associated with these risk factors involving the
hospital stay of patients with myalgia. METHODS: Data were
collected from hospitals around the United States through the
NIS, and these data were narrowed down to those patients
suffering from myalgia. These data were then analyzed using SAS
Enterprise Guide 4. Data visualization techniques, logistic regres-
sion and linear models were used to achieve the desired results.
RESULTS: It was determined that females are the most abundant
among myalgia sufferers with a peak age around 56. The male
subjects with myalgia had a broad peak of 43 to 65 years of age.
This condition has occurred in most women by the age of 58. It
was also determined that the Asian/Paciﬁc Islanders demon-
strated a peak age of around 70 in comparison to the average age
of 58.3. Asians have the lowest probability of accumulating
less than $20,000 in total charges and Caucasians, African-
Americans, and Native Americans have the highest. Asians also
have the highest probability among the races of accumulating
between $38,000 and $58,000 in charges. Caucasians were
determined to have the least probability of staying less than ﬁve
days in the hospital and Asians have the highest probability of
staying between 11 and 16 days. A linear model revealed that the
following DX and DRG codes are signiﬁcant in predicting total
charges and also surround heart and blood conditions: Transfu-
sion of packed cells, anemia (unspeciﬁed), venous catheterization
(not elsewhere classiﬁed), of native coronary artery, congestive
heart failure (unspeciﬁed), and atrial ﬁbrillation. CONCLU-
SION: There is currently limited data on the risk factors of
myalgia and these results will hopefully be a start to learning
more about the condition.
A154 Abstracts
